Replies to post #112705 on Amarin Corp Plc (AMRN)

[Biobillionair]

Amarin should bank on R-I success, at bare minimum this trial finishes with a RRR>7%. With the patient population (placebo rate), extend of trial (Patient Years), and timing of final event Q1 2018 (I think Q2 2018) it's not statistically possible for trial to fail. (Fail is <7% RRR Vytorin FDA regulatory mark)

The placebo rate will have to be UNDER 5% to fail!!!!

This is beyond an asymmetrical bet JL likes to quote.

I want the company to raise $100 million NOW, first asking the top 5% to buy-in at $5, if this does not get interest Amarin should raise $100 million at market, hire full R-I staff, train, and immediately sell off label with Q2/3 announcement of top line R-I results.

Get it done JT!!! (& Board)

Shame on AMRN investors that expected trial to halt, Amarin was very clear it was highly unlikely!!!! Amarin is going for secondaries, the trial WILL NOT HALT ON PRIMARY GOAL OF A STUPID 15% reduction in CVE!!! R-I is a paradigm shift not the study of another failed PCSK9.....

BB

[marzan]

BB, I welcome your idea. Raise $100M at $5 or $3 and go even stronger to the RI results. Why not? we are already at $3. Raising at $3 will not be a difficult, imo. JT et al should seriously consider this in the absence of no new deals or partnership in the horizon until RI results. I like it. We should it without any further delay. And when we have money, pps will go up later.